IN ALRN 001Alternative Names: IN-ALRN-001
Latest Information Update: 08 Sep 2016
At a glance
- Originator Intas Pharmaceuticals
- Mechanism of Action Undefined mechanism
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Benign prostatic hyperplasia
Most Recent Events
- 08 Sep 2016 No development reported - Phase-III for Benign prostatic hyperplasia in India (unspecified route)